Compounds > indazoles
Page last updated: 2024-08-21

indazoles and Hereditary Hemorrhagic Telangiectasia

indazoles has been researched along with Hereditary Hemorrhagic Telangiectasia in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Ajebo, EM; Belcher, MD; Gossage, JR; Moon, JY1
Stretton, O1
Al-Samkari, H; Gossage, JR; McCrae, KR; Menon, KVN; Parambil, JG; Pederson, DP; Sprecher, DL; Timmerman, KL; Woodard, TD1
Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D1
Koc, ON; Parambil, JG; Woodard, TD1
Berry, P; Chakinala, MM; Donaldson, J; Faughnan, ME; Gossage, JR; Hughes, CCW; Kasthuri, R; McWilliams, JP; Oh, SP; Parambil, JG; Paul, G; Sprecher, DL; Vozoris, N1

Trials

1 trial(s) available for indazoles and Hereditary Hemorrhagic Telangiectasia

ArticleYear
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia.
    Angiogenesis, 2019, Volume: 22, Issue:1

    Topics: Adult; Female; Hemorrhage; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic

2019

Other Studies

5 other study(ies) available for indazoles and Hereditary Hemorrhagic Telangiectasia

ArticleYear
Improvement of Cutaneous Hereditary Hemorrhagic Telangiectasia With Pazopanib-A Multikinase Inhibitor.
    JAMA dermatology, 2022, 02-01, Volume: 158, Issue:2

    Topics: Humans; Indazoles; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic

2022
EHA 2021 Virtual Congress.
    The Lancet. Haematology, 2021, Volume: 8, Issue:8

    Topics: Activin Receptors, Type II; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; beta-Thalassemia; Graft vs Host Disease; Hematologic Diseases; Humans; Immunoglobulin Fc Fragments; Indazoles; Interleukin-1 Receptor-Associated Kinases; Internet; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Fusion Proteins; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic

2021
Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.
    Angiogenesis, 2022, Volume: 25, Issue:1

    Topics: Anemia; Epistaxis; Humans; Indazoles; Pyrimidines; Retrospective Studies; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic

2022
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:6

    Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing

2017
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    The Laryngoscope, 2018, Volume: 128, Issue:10

    Topics: Anemia, Iron-Deficiency; Angiogenesis Inhibitors; Bevacizumab; Epistaxis; Erythrocyte Transfusion; Hemoglobins; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic

2018